急性心肌梗死合并心源性休克经皮冠状动脉介入治疗并Impella支持:高龄与难治性休克对结局的影响
该单中心回顾性研究纳入2018年1月1日至2019年12月31日期间31例因急性心肌梗死合并心源性休克接受Impella Cardiac Pow支持的连续成人患者,按心血管造影与介入学会(SCAI)休克分期A-E分层,主要终点为院内死亡。总体院内死亡率为61%;E期10例(32%)全部院内死亡;<80岁患者死亡率为54%(13/24),≥80岁为86%(6/7)。Valve Academic Research Consortium-2出血事件占38.7%(12/31)、血管事件占32.3%(10/31),在各SCAI分期分布均匀。作者认为,极度休克(E期)及≥80岁患者即使使用Impella死亡率可能高得难以接受,需更大样本前瞻性研究进一步评估。
要点
- 31例急性心肌梗死合并心源性休克接受Impella Cardiac Pow支持的患者总体院内死亡率为61%。
- SCAI E期10例(32%)全部院内死亡,<80岁死亡率54%(13/24)vs ≥80岁86%(6/7)。
- Valve Academic Research Consortium-2出血事件38.7%(12/31)、血管事件32.3%(10/31),各SCAI分期分布均匀。
- 研究人群中位年龄64岁,≥80岁7例(23%);无A期患者,B期7例、C期8例、D期6例、E期10例。
- 作者认为极度休克及≥80岁患者即使使用Impella死亡率可能高得难以接受,需更大样本前瞻性研究评估。
适用人群与场景
- 2018年1月1日至2019年12月31日期间单家社区医院连续纳入的31例因急性心肌梗死合并心源性休克接受Impella Cardiac Pow支持的成人患者。
- 按心血管造影与介入学会(SCAI)休克分期A-E分层:无A期,B期7例、C期8例、D期6例、E期10例(32%)。
- 中位年龄64岁,≥80岁7例(23%),<80岁24例。
诊断标准与关键阈值
- 心源性休克分期采用心血管造影与介入学会(SCAI)分期(A-E期)。
- 年龄分层界值:≥80岁与<80岁。
红旗征与不能漏的情况
- SCAI E期(极度休克)患者10例全部院内死亡。
- ≥80岁患者院内死亡率86%(6/7),<80岁为54%(13/24)。
研究设计与关键结果
- 研究类型:回顾性综述(Retrospective review),单家社区医院,2018年1月1日至2019年12月31日,31例连续成人患者。
- 干预:无(观察性研究),患者均接受Impella Cardiac Pow支持。
- 主要终点院内死亡:总体61%;SCAI E期10例全部院内死亡;<80岁54%(13/24)vs ≥80岁86%(6/7)。
- 次要终点Valve Academic Research Consortium-2出血事件38.7%(12/31)、血管事件32.3%(10/31),各SCAI分期分布均匀;原文未报告卒中及需透析的肾衰竭的具体结果数值。
证据类型、等级与局限
- 证据类型:单中心回顾性综述。
- 局限:原文报告样本量小(31例),作者指出需更大样本前瞻性研究进一步评估Impella及其他左心室机械循环支持装置在晚期心源性休克及老年患者中的有效性及固有资源利用。
对床旁实践的改变
- 作者认为,极度休克(SCAI E期)及≥80岁患者即使使用Impella死亡率可能高得难以接受。
- 作者指出这些发现需更大样本前瞻性研究评估Impella及其他左心室机械循环支持装置在晚期心源性休克及老年患者中的有效性及固有资源利用。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
UNLABELLED: With percutaneous left ventricular mechanical circulatory support devices becoming increasingly available for patients with cardiogenic shock due to acute myocardial infarction and the lack of a clear mortality benefit to date, identifying optimal candidates for this technology is crucial. We studied the effectiveness of Impella Cardiac Pow (Abiomed, Danvers, MA) in various stages of cardiogenic shock and elderly cohorts.
DESIGN: Retrospective review.
SETTING: Data were collected for patients at a single community hospital between January 1, 2018, and December 31, 2019.
SUBJECTS: Thirty-one consecutive adult patients with cardiogenic shock due to acute myocardial infarction who received Impella Cardiac Pow support. Shock stages were defined by the Society for Cardiovascular Angiography and Intervention (Stages A-E).
INTERVENTIONS: None.
MEASUREMENTS AND MAIN RESULTS: The primary outcome was in-hospital death across Society for Cardiovascular Angiography and Intervention cardiogenic shock stages and in patients greater than or equal to 80 and less than 80 years old. Secondary outcomes were Valve Academic Research Consortium-2 vascular and bleeding complications, stroke, and renal failure requiring dialysis. The median age of the study population was 64 years, with seven patients (23%) being greater than or equal to 80 years old. No patients were in Society for Cardiovascular Angiography and Intervention Stage A, whereas there were seven in B, eight in C, six in D, and 10 (32%) in E. Overall in-hospital mortality occurred in 61% of patients. All 10 patients in Stage E died before hospital discharge. Mortality occurred in 54% of patients (13/24) age less than 80 years compared with 86% of those 80 years or older (6/7). A total of 38.7% of patients (12/31) and 32.3% of patients (10/31) experienced Valve Academic Research Consortium-2 bleeding and vascular events, which were evenly distributed across Society for Cardiovascular Angiography and Intervention cardiogenic shock Stages.
CONCLUSIONS: In conclusion, patients with shock in extremis and those 80 years old and older may have a prohibitively high mortality despite Impella use. These findings merit further prospective investigation in a larger number of patients to evaluate the effectiveness of Impella (and other left ventricular mechanical circulatory devices) and the inherent resource utilization in advanced cardiogenic shock and the elderly.
参考来源
- Boshara A, Patel A, Alasaad M, et al. Cardiogenic Shock Complicating Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention Supported by Impella: Implications of Advanced Age and Refractory Shock on Outcomes. Crit Care Explor. 2021. PMID: 34136823. doi:10.1097/CCE.0000000000000447
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。